News
STTK
5.67
+5.19%
0.28
Weekly Report: what happened at STTK last week (0615-0619)?
Weekly Report · 2d ago
Weekly Report: what happened at STTK last week (0608-0612)?
Weekly Report · 06/15 09:50
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
NASDAQ · 06/15 02:02
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 06/12 17:05
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday
Benzinga · 06/12 14:09
Insider Power Play: Shattuck Labs Director Makes Bold Stock Move
TipRanks · 06/12 02:01
Shattuck Labs director Clay B. Siegall buys 62,500 common shares for $250,000
PUBT · 06/11 21:00
Shattuck Labs Prices Upsized Public Equity and Warrant Offering
TipRanks · 06/11 12:45
BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
Reuters · 06/10 15:40
What's Going On With Shattuck Labs Stock Wednesday?
Benzinga · 06/10 13:40
BUZZ-U.S. STOCKS ON THE MOVE-Cracker Barrel, Tango Therapeutics, Chewy
Reuters · 06/10 13:07
BUZZ-U.S. STOCKS ON THE MOVE-Nike, Shattuck Labs, Centene
Reuters · 06/10 12:06
BUZZ-Shattuck Labs drops on $75 mln share sale
Reuters · 06/10 11:02
Shattuck Labs drops 6%, prices $75M share raise at $4 per share
Seeking Alpha · 06/10 10:37
Shattuck Labs: "Hold" On Phase 1  SL-325 Data And Next Stage Of Development
Seeking Alpha · 06/10 10:28
Shattuck Labs 10.9M share Spot Secondary priced at $4.00
TipRanks · 06/10 10:05
Shattuck Labs Prices $75 Mln Offering Of Shares And Warrants; Stock Down
NASDAQ · 06/10 09:16
*Shattuck Labs Expects Gross Proceeds of About $75M From Offering >STTK
Dow Jones · 06/10 04:29
*Shattuck Labs Prices 10.9M Public Offering Shares at $4.00 Each >STTK
Dow Jones · 06/10 04:29
*Shattuck Labs Prices Prefunded Warrants to Purchase Up to 7.9M Shares at Public Offering Price of $3.999 Each >STTK
Dow Jones · 06/10 04:29
More
Webull provides a variety of real-time STTK stock news. You can receive the latest news about Shattuck Labs, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.